NASDAQ Stock Exchange News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 966,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "33bb59f7-acaf-4e7c-8d80-0d1e95e9d82e",
"title": "Open Source Service Market to Flourish at 16.5% CAGR, Hitting US$ 141.0 Billion by 2034 | Future Market Insights, Inc.",
"description": "The United States is unequivocally establishing itself as a powerhouse in the open source service market, boasting an impressive projected CAGR of 16.8%...",
"keywords": "Future Market Insights Global and Consulting Pvt. Ltd., Open Source Service Market, Open Source Service Industry, Open Source Service, Open Source Service Size",
"snippet": "NEWARK, Del, March 28, 2024 (GLOBE NEWSWIRE) -- The open source service market is expected to experience substantial growth, with a projected valuation of US$ 3...",
"url": "https://www.globenewswire.com/news-release/2024/03/29/2854601/0/en/Open-Source-Service-Market-to-Flourish-at-16-5-CAGR-Hitting-US-141-0-Billion-by-2034-Future-Market-Insights-Inc.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/915d2f9c-7dc6-40c7-995c-2ba168208baa",
"language": "en",
"published_at": "2024-03-29T00:30:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "GOOG",
"name": "Alphabet Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 6.356328,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(Amazon)\n\nDatabricks\n\nHashiCorp\n\n<em>Alphabet</em>, <em>Inc</em>. (Google)\n\nMicrosoft\n\nSAP SE\n\nIBM Corporation\n\nOracle Corporation\n\nAccenture Plc.\n\nWipro Limited\n\nCisco System, Inc.\n\nSUSE\n\nViSolve.Com\n\nHewlett Packard Enterprise Development LP\n\nInfosys Limited\n\nKubermatic GmbH\n\nSeize the Opportunity: Buy Now for a Thorough Report!",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GOOGL",
"name": "Alphabet Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 9.815876,
"sentiment_score": 0,
"highlights": [
{
"highlight": "(Amazon)\n\nDatabricks\n\nHashiCorp\n\n<em>Alphabet</em>, <em>Inc</em>. (Google)\n\nMicrosoft\n\nSAP SE\n\nIBM Corporation\n\nOracle Corporation\n\nAccenture Plc.\n\nWipro Limited\n\nCisco System, Inc.\n\nSUSE\n\nViSolve.Com\n\nHewlett Packard Enterprise Development LP\n\nInfosys Limited\n\nKubermatic GmbH\n\nSeize the Opportunity: Buy Now for a Thorough Report!",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "6c9990d3-9a73-4ebd-97bb-eecdf7401873",
"title": "[Latest] Global Cancer Immunotherapy Market Size/Share Worth USD 314.4 Billion by 2032 at a 7.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growt",
"description": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cancer Immunotherapy...",
"keywords": "CMI MARKET RESEARCH PRIVATE LIMITED, Cancer, Immunotherapy, mAbs, ACT, Inhibitors, Vaccines, Cytokine, Lung, Breast, Colorectal, Melanoma, Prostate, Leukemia, Oral, IV, Intramuscular, CMI, AI",
"snippet": "Austin, TX, USA, March 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Immunotherapy Market Size, Trend...",
"url": "https://www.globenewswire.com/news-release/2024/03/28/2854419/0/en/Latest-Global-Cancer-Immunotherapy-Market-Size-Share-Worth-USD-314-4-Billion-by-2032-at-a-7-2-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-Segmentati.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/74609d89-5437-4826-b7b8-31238ea2e65c",
"language": "en",
"published_at": "2024-03-28T19:30:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 5.676787,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Bristol Myers Squibb Company\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\n<em>Pfizer</em> <em>Inc</em>.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 5.676787,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Bristol Myers Squibb Company\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\n<em>Pfizer</em> <em>Inc</em>.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 6.911778,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Bristol Myers Squibb Company\n\nAstraZeneca plc\n\n<em>Johnson</em> & <em>Johnson</em>\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RHHBY",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 9.343124,
"sentiment_score": -0.3404,
"highlights": [
{
"highlight": "Cancer Research Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\n<em>Roche</em>",
"sentiment": -0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Holding</em> <em>AG</em>\n\nMerck & Co.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.561661,
"sentiment_score": 0.05135,
"highlights": [
{
"highlight": "reportid=43173\n\nCancer Immunotherapy Market: Partnership and Acquisitions\n\nIn 2023, <em>AstraZeneca</em> obtained European Union approval for the tablet formulation of Calquence (acalabrutinib) to treat Chronic Lymphocytic Leukaemia (CLL) in adults.",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Bristol Myers Squibb Company\n\n<em>AstraZeneca</em> <em>plc</em>\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RHHBF",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 9.343126,
"sentiment_score": -0.3404,
"highlights": [
{
"highlight": "Cancer Research Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\n<em>Roche</em>",
"sentiment": -0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Holding</em> <em>AG</em>\n\nMerck & Co.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RHHVF",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 9.343126,
"sentiment_score": -0.3404,
"highlights": [
{
"highlight": "Cancer Research Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\n<em>Roche</em>",
"sentiment": -0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Holding</em> <em>AG</em>\n\nMerck & Co.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.561711,
"sentiment_score": 0.05135,
"highlights": [
{
"highlight": "reportid=43173\n\nCancer Immunotherapy Market: Partnership and Acquisitions\n\nIn 2023, <em>AstraZeneca</em> obtained European Union approval for the tablet formulation of Calquence (acalabrutinib) to treat Chronic Lymphocytic Leukaemia (CLL) in adults.",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Bristol Myers Squibb Company\n\n<em>AstraZeneca</em> <em>plc</em>\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BRM.DE",
"name": "Bristol-Myers Squibb Company",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.372467,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Bristol</em> <em>Myers</em> <em>Squibb</em> <em>Company</em>\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE.DE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 5.676745,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Bristol Myers Squibb Company\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\n<em>Pfizer</em> <em>Inc</em>.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GIS.DE",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.474705,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Eli Lilly and Company\n\n<em>Gilead</em> <em>Sciences</em> <em>Inc</em>.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "6MK.DE",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 7.274015,
"sentiment_score": -0.0172,
"highlights": [
{
"highlight": "Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\nRoche Holding AG\n\n<em>Merck</em>",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "& <em>Co</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em>.\n\nBristol Myers Squibb Company\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY.DE",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.933731,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AMG.DE",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 7.010294,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Amgen</em> <em>Inc</em>.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.PA",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "fr",
"type": "equity",
"industry": "Healthcare",
"match_score": 7.273766,
"sentiment_score": -0.0172,
"highlights": [
{
"highlight": "Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\nRoche Holding AG\n\n<em>Merck</em>",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "& <em>Co</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em>.\n\nBristol Myers Squibb Company\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNN.MX",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.561536,
"sentiment_score": 0.05135,
"highlights": [
{
"highlight": "reportid=43173\n\nCancer Immunotherapy Market: Partnership and Acquisitions\n\nIn 2023, <em>AstraZeneca</em> obtained European Union approval for the tablet formulation of Calquence (acalabrutinib) to treat Chronic Lymphocytic Leukaemia (CLL) in adults.",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Bristol Myers Squibb Company\n\n<em>AstraZeneca</em> <em>plc</em>\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BMY.MX",
"name": "Bristol-Myers Squibb Company",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.371834,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Bristol</em> <em>Myers</em> <em>Squibb</em> <em>Company</em>\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD.MX",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.473618,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Eli Lilly and Company\n\n<em>Gilead</em> <em>Sciences</em> <em>Inc</em>.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ROGN.MX",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 9.343334,
"sentiment_score": -0.3404,
"highlights": [
{
"highlight": "Cancer Research Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\n<em>Roche</em>",
"sentiment": -0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Holding</em> <em>AG</em>\n\nMerck & Co.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE.MX",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 5.676782,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Bristol Myers Squibb Company\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\n<em>Pfizer</em> <em>Inc</em>.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.MX",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 7.273862,
"sentiment_score": -0.0172,
"highlights": [
{
"highlight": "Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\nRoche Holding AG\n\n<em>Merck</em>",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "& <em>Co</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em>.\n\nBristol Myers Squibb Company\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN.MX",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.051483,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Sanofi\n\n<em>Regeneron</em> <em>Pharmaceuticals</em> <em>Inc</em>.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.561539,
"sentiment_score": 0.05135,
"highlights": [
{
"highlight": "reportid=43173\n\nCancer Immunotherapy Market: Partnership and Acquisitions\n\nIn 2023, <em>AstraZeneca</em> obtained European Union approval for the tablet formulation of Calquence (acalabrutinib) to treat Chronic Lymphocytic Leukaemia (CLL) in adults.",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Bristol Myers Squibb Company\n\n<em>AstraZeneca</em> <em>plc</em>\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AMGN",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 7.009972,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Amgen</em> <em>Inc</em>.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.472656,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Eli Lilly and Company\n\n<em>Gilead</em> <em>Sciences</em> <em>Inc</em>.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.05093,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Sanofi\n\n<em>Regeneron</em> <em>Pharmaceuticals</em> <em>Inc</em>.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.932821,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BMY",
"name": "Bristol-Myers Squibb Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.371101,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Bristol</em> <em>Myers</em> <em>Squibb</em> <em>Company</em>\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 7.273782,
"sentiment_score": -0.0172,
"highlights": [
{
"highlight": "Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\nRoche Holding AG\n\n<em>Merck</em>",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "& <em>Co</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em>.\n\nBristol Myers Squibb Company\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LLY.MX",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.932913,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AMGN.MX",
"name": "Amgen Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 7.007959,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Amgen</em> <em>Inc</em>.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZN.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.561545,
"sentiment_score": 0.05135,
"highlights": [
{
"highlight": "reportid=43173\n\nCancer Immunotherapy Market: Partnership and Acquisitions\n\nIn 2023, <em>AstraZeneca</em> obtained European Union approval for the tablet formulation of Calquence (acalabrutinib) to treat Chronic Lymphocytic Leukaemia (CLL) in adults.",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Bristol Myers Squibb Company\n\n<em>AstraZeneca</em> <em>plc</em>\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0TDF.L",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 9.343594,
"sentiment_score": -0.3404,
"highlights": [
{
"highlight": "Cancer Research Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\n<em>Roche</em>",
"sentiment": -0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Holding</em> <em>AG</em>\n\nMerck & Co.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0A4J.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 8.561461,
"sentiment_score": 0.05135,
"highlights": [
{
"highlight": "reportid=43173\n\nCancer Immunotherapy Market: Partnership and Acquisitions\n\nIn 2023, <em>AstraZeneca</em> obtained European Union approval for the tablet formulation of Calquence (acalabrutinib) to treat Chronic Lymphocytic Leukaemia (CLL) in adults.",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Bristol Myers Squibb Company\n\n<em>AstraZeneca</em> <em>plc</em>\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0QQ6.L",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 9.343573,
"sentiment_score": -0.3404,
"highlights": [
{
"highlight": "Cancer Research Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\n<em>Roche</em>",
"sentiment": -0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Holding</em> <em>AG</em>\n\nMerck & Co.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0R2M.L",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 11.049622,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Sanofi\n\n<em>Regeneron</em> <em>Pharmaceuticals</em> <em>Inc</em>.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0Q1G.L",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 10.932201,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ROG.SW",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "ch",
"type": "equity",
"industry": "Healthcare",
"match_score": 9.343615,
"sentiment_score": -0.3404,
"highlights": [
{
"highlight": "Cancer Research Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\n<em>Roche</em>",
"sentiment": -0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Holding</em> <em>AG</em>\n\nMerck & Co.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RO.SW",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "ch",
"type": "equity",
"industry": "Healthcare",
"match_score": 9.343615,
"sentiment_score": -0.3404,
"highlights": [
{
"highlight": "Cancer Research Institutes, Clinics, Ambulatory Surgical Centers (ASCs), Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033” Report at https://www.custommarketinsights.com/report/cancer-immunotherapy-market/\n\nList of the prominent players in the Cancer Immunotherapy Market:\n\n<em>Roche</em>",
"sentiment": -0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Holding</em> <em>AG</em>\n\nMerck & Co.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BMYB34.SA",
"name": "Bristol-Myers Squibb Company",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.369774,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Bristol</em> <em>Myers</em> <em>Squibb</em> <em>Company</em>\n\nAstraZeneca plc\n\nJohnson & Johnson\n\nNovartis International AG\n\nPfizer Inc.\n\nAmgen Inc.\n\nEli Lilly and Company\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LILY34.SA",
"name": "Eli Lilly and Company",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.931852,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Eli</em> <em>Lilly</em> <em>and</em> <em>Company</em>\n\nGilead Sciences Inc.\n\nSanofi\n\nRegeneron Pharmaceuticals Inc.\n\nSeattle Genetics Inc.\n\nGenentech Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "84f01a48-23b4-4b12-9606-7b46ae6458d6",
"title": "US Equities Surge, Asian Markets Poised for Gains Amid Fed Soft Landing Hopes",
"description": "Asian equity markets are expected to open higher following a remarkable quarter for US stocks, fueled by optimism that the Federal Reserve can manage a soft lan",
"keywords": "GuruFocus, Article, News, GuruFocus Research, AAPL, HD, WBA, RILY, PLTR, EL, 2007",
"snippet": "Asian equity markets are expected to open higher following a remarkable quarter for US stocks, fueled by optimism that the Federal Reserve can manage a soft lan...",
"url": "https://www.gurufocus.com/news/2399871/us-equities-surge-asian-markets-poised-for-gains-amid-fed-soft-landing-hopes",
"image_url": "https://static.gurufocus.com/logos/0C00000ADA.png?20",
"language": "en",
"published_at": "2024-03-29T00:17:23.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AAPL",
"name": "Apple Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 12.924612,
"sentiment_score": -0.3612,
"highlights": [
{
"highlight": "Corporate highlights include <em>Apple</em> <em>Inc</em>. gearing up for new iPad launches, Home Depot Inc.'s debt plans for an acquisition, and Walgreens Boots Alliance Inc. adjusting its fiscal guidance. Additionally, B.",
"sentiment": -0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "WBA",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 45.76989,
"sentiment_score": -0.3612,
"highlights": [
{
"highlight": "s debt plans for an acquisition, and <em>Walgreens</em> <em>Boots</em> <em>Alliance</em> <em>Inc</em>. adjusting its fiscal guidance. Additionally, B. Riley Financial Inc. secures more time for financial reporting, Palantir Technologies Inc. faces a downgrade, Estee Lauder Cos. receives an upgrade, and Country Garden Holdings Co. warns of delayed financial results.",
"sentiment": -0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RILY",
"name": "B. Riley Financial, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 33.116234,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Additionally, <em>B</em>. <em>Riley</em> <em>Financial</em> <em>Inc</em>. secures more time for financial reporting, Palantir Technologies Inc. faces a downgrade, Estee Lauder Cos. receives an upgrade, and Country Garden Holdings Co. warns of delayed financial results.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RILYH",
"name": "B. Riley Financial, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 33.116234,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Additionally, <em>B</em>. <em>Riley</em> <em>Financial</em> <em>Inc</em>. secures more time for financial reporting, Palantir Technologies Inc. faces a downgrade, Estee Lauder Cos. receives an upgrade, and Country Garden Holdings Co. warns of delayed financial results.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RILYP",
"name": "B. Riley Financial, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 33.116234,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Additionally, <em>B</em>. <em>Riley</em> <em>Financial</em> <em>Inc</em>. secures more time for financial reporting, Palantir Technologies Inc. faces a downgrade, Estee Lauder Cos. receives an upgrade, and Country Garden Holdings Co. warns of delayed financial results.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RILYL",
"name": "B. Riley Financial, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 33.116234,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Additionally, <em>B</em>. <em>Riley</em> <em>Financial</em> <em>Inc</em>. secures more time for financial reporting, Palantir Technologies Inc. faces a downgrade, Estee Lauder Cos. receives an upgrade, and Country Garden Holdings Co. warns of delayed financial results.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "eff36690-599c-4a1b-a968-b7f6bc7a4fad",
"title": "IRTC DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages iRhythm Technologies, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important April 8 Deadline in Securities Class Action –",
"description": "NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of iRhythm...",
"keywords": "The Rosen Law Firm PA, iRhythm Technologies, Inc., Rosen Law Firm, NASDAQ: IRTC, Class Action",
"snippet": "NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of iRhythm Technologies...",
"url": "https://www.globenewswire.com/news-release/2024/03/29/2854600/673/en/IRTC-DEADLINE-TOP-RANKED-ROSEN-LAW-FIRM-Encourages-iRhythm-Technologies-Inc-Investors-With-Losses-in-Excess-of-100K-to-Secure-Counsel-Before-Important-April-8-Deadline-in-Securitie.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/745335af-3a3a-4fb5-84c0-fdedc9adf092",
"language": "en",
"published_at": "2024-03-29T00:08:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "IRTC",
"name": "iRhythm Technologies, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 98.80322,
"sentiment_score": 0.5003,
"highlights": [
{
"highlight": "NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of <em>iRhythm</em> <em>Technologies</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>IRTC</em>) between January 11, 2022 and May 30, 2023, both dates inclusive (the “Class Period”), of the important April 8, 2024 lead plaintiff deadline.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "IRTC DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages <em>iRhythm</em> <em>Technologies</em>, <em>Inc</em>. Investors With Losses in Excess of $100K to Secure Counsel Before Important April 8 Deadline in Securities Class Action –",
"sentiment": 0.7983,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "022d02fc-ec72-45fc-aaeb-c3f4ce749996",
"title": "ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Plug Power Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PLUG",
"description": "NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on...",
"keywords": "The Rosen Law Firm PA, Plug Power Inc., PLUG, Class Action",
"snippet": "NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf o...",
"url": "https://www.globenewswire.com/news-release/2024/03/28/2854414/673/en/ROSEN-TOP-RANKED-GLOBAL-COUNSEL-Encourages-Plug-Power-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-PLUG.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/745335af-3a3a-4fb5-84c0-fdedc9adf092",
"language": "en",
"published_at": "2024-03-28T19:11:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "PLUN.DE",
"name": "Plug Power Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Industrials",
"match_score": 82.91781,
"sentiment_score": 0.252971,
"highlights": [
{
"highlight": "NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of <em>Plug</em> <em>Power</em> <em>Inc</em>. (NASDAQ: PLUG) between May 9, 2023 and January 16, 2024, both dates inclusive (the “Class Period”).",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "SO WHAT: If you purchased <em>Plug</em> <em>Power</em> securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.\n\nWHAT TO DO NEXT: To join the <em>Plug</em> <em>Power</em> class action, go to https://rosenlegal.com/submit-form/?",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) <em>Plug</em> <em>Power</em> overstated its ability and/or efforts to mitigate the negative impacts that, inter alia, supply chain constraints and material shortages could have or were having on Plug Power’s",
"sentiment": -0.872,
"highlighted_in": "main_text"
},
{
"highlight": "hydrogen business, as well as the sufficiency of its cash and capital to fund its operations; (2) <em>Plug</em> <em>Power</em> continued to experience delays related to its green hydrogen production facility build-out plans, as well as in securing external funding sources to finance its growth plans; (3) <em>Plug</em> <em>Power</em> downplayed the true scope and severity of all the foregoing",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "when these issues were eventually revealed; (4) as a result of all the foregoing, <em>Plug</em> <em>Power</em> also overstated the near-term prospects of its hydrogen production operations, as well as the viability of expanding those operations; and (5) as a result, Plug Power’s public statements were materially false and misleading at all relevant times.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "To join the <em>Plug</em> <em>Power</em> class action, go to https://rosenlegal.com/submit-form/?case_id=1011 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.\n\nNo Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages <em>Plug</em> <em>Power</em> <em>Inc</em>. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PLUG",
"sentiment": 0.87,
"highlighted_in": "title"
}
]
},
{
"symbol": "PLUG",
"name": "Plug Power Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 95.11258,
"sentiment_score": 0.252971,
"highlights": [
{
"highlight": "NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of <em>Plug</em> <em>Power</em> <em>Inc</em>. (<em>NASDAQ</em>: <em>PLUG</em>) between May 9, 2023 and January 16, 2024, both dates inclusive (the “Class Period”).",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "SO WHAT: If you purchased <em>Plug</em> <em>Power</em> securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.\n\nWHAT TO DO NEXT: To join the <em>Plug</em> <em>Power</em> class action, go to https://rosenlegal.com/submit-form/?",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) <em>Plug</em> <em>Power</em> overstated its ability and/or efforts to mitigate the negative impacts that, inter alia, supply chain constraints and material shortages could have or were having on Plug Power’s",
"sentiment": -0.872,
"highlighted_in": "main_text"
},
{
"highlight": "hydrogen business, as well as the sufficiency of its cash and capital to fund its operations; (2) <em>Plug</em> <em>Power</em> continued to experience delays related to its green hydrogen production facility build-out plans, as well as in securing external funding sources to finance its growth plans; (3) <em>Plug</em> <em>Power</em> downplayed the true scope and severity of all the foregoing",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "when these issues were eventually revealed; (4) as a result of all the foregoing, <em>Plug</em> <em>Power</em> also overstated the near-term prospects of its hydrogen production operations, as well as the viability of expanding those operations; and (5) as a result, Plug Power’s public statements were materially false and misleading at all relevant times.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "To join the <em>Plug</em> <em>Power</em> class action, go to https://rosenlegal.com/submit-form/?case_id=1011 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.\n\nNo Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages <em>Plug</em> <em>Power</em> <em>Inc</em>. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PLUG",
"sentiment": 0.87,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "c9cd372a-dc84-40d2-ace5-4662ec92bfae",
"title": "Affirm : CFO Fireside Chat Transcript -March 28, 2024 at 08:00 pm EDT",
"description": "Affirm Holdings, Inc. NasdaqGS:AFRM\n \n \n Affirm Fireside Chat with Wells Fargo\n \n \n Friday, March 22, 2024 4:00 PM GMT\n \n \n Call...",
"keywords": "Markets",
"snippet": "Affirm Holdings, Inc. NasdaqGS:AFRM\n\nAffirm Fireside Chat with Wells Fargo\n\nFriday, March 22, 2024 4:00 PM GMT\n\nCall Participants\n\nEXECUTIVES\n\nMichael A. Linfor...",
"url": "https://www.marketscreener.com/quote/stock/AFFIRM-HOLDINGS-INC-117540803/news/Affirm-CFO-Fireside-Chat-Transcript-46315999/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-03-29T00:00:12.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "AFRM",
"name": "Affirm Holdings, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 4.976517,
"sentiment_score": 0.25,
"highlights": [
{
"highlight": "<em>Affirm</em> <em>Holdings</em>, <em>Inc</em>. NasdaqGS:AFRM\n\nAffirm Fireside Chat with Wells Fargo\n\nFriday, March 22, 2024 4:00 PM GMT\n\nCall Participants\n\nEXECUTIVES\n\nMichael A.",
"sentiment": 0.25,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "2ab4bdb6-d6df-47db-a2c1-1d5dd4c30a78",
"title": "Skyworks : 2023 Annual Report and 2024 Proxy Statement, Proxy Card and Notice -March 28, 2024 at 06:23 pm EDT",
"description": "March 28, 2024\n \n \n Dear Stockholder:\n \n \n I am pleased to invite you to attend the 2024 Annual Meeting of Stockholders of Skyworks Solutions, Inc.,...",
"keywords": "Markets",
"snippet": "March 28, 2024\n\nDear Stockholder:\n\nI am pleased to invite you to attend the 2024 Annual Meeting of Stockholders (the \"Annual Meeting\") of Skyworks Solutions, In...",
"url": "https://www.marketscreener.com/quote/stock/SKYWORKS-SOLUTIONS-INC-11014/news/Skyworks-2023-Annual-Report-and-2024-Proxy-Statement-Proxy-Card-and-Notice-46315719/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-03-28T22:23:56.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "AWM.DE",
"name": "Skyworks Solutions, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Technology",
"match_score": 14.441595,
"sentiment_score": 0.7269,
"highlights": [
{
"highlight": "March 28, 2024\n\nDear Stockholder:\n\nI am pleased to invite you to attend the 2024 Annual Meeting of Stockholders (the \"Annual Meeting\") of <em>Skyworks</em> <em>Solutions</em>, <em>Inc</em>., to be held at:\n\nTime: 11:00 a.m.",
"sentiment": 0.7269,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "^GSPC",
"name": "S&P 500",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "index",
"industry": "N/A",
"match_score": 9.399117,
"sentiment_score": 0.39745,
"highlights": [
{
"highlight": "per share to $0.68 per share\n\n• Returned approximately $580 million to stockholders through repurchasing 1.9 million shares of our common stock for $175 million and through payments of $405 million in cash dividends\n\n• Repaid $900 million of debt\n\n• Total stockholder return over the last 10 years was 360%, compared to 208% for the companies in the <em>S</em>&",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>P</em> <em>500</em> Index(2)\n\nQuarterly Dividends: Fiscal Years 2015 - 2023 $2.54\n\n$2.30\n\n$2.06\n\n$1.82\n\nQ4\n\nQ3\n\n$0.44 $0.50\n\n$1.58\n\n$1.34\n\n$0.50\n\n$0.56\n\n$0.62\n\n$0.68\n\n$1.06\n\n$1.16 $0.38\n\n$0.62\n\n$0.65\n\nQ2\n\nQ1\n\n$0.13 $0.13 $0.13\n\n$0.26 $0.26 $0.26\n\n$0.32\n\n$0.62 $0.56\n\n$0.28\n\nFY15\n\nFY16\n\nFY17\n\nFY18\n\nFY19\n\nFY20\n\nFY21\n\nFY22\n\nFY23\n\n(1) Please see table on page 110 for",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "^SPX",
"name": "S&P 500 INDEX",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "index",
"industry": "N/A",
"match_score": 13.123074,
"sentiment_score": 0.39745,
"highlights": [
{
"highlight": "per share to $0.68 per share\n\n• Returned approximately $580 million to stockholders through repurchasing 1.9 million shares of our common stock for $175 million and through payments of $405 million in cash dividends\n\n• Repaid $900 million of debt\n\n• Total stockholder return over the last 10 years was 360%, compared to 208% for the companies in the <em>S</em>&",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>P</em> <em>500</em> <em>Index</em>(2)\n\nQuarterly Dividends: Fiscal Years 2015 - 2023 $2.54\n\n$2.30\n\n$2.06\n\n$1.82\n\nQ4\n\nQ3\n\n$0.44 $0.50\n\n$1.58\n\n$1.34\n\n$0.50\n\n$0.56\n\n$0.62\n\n$0.68\n\n$1.06\n\n$1.16 $0.38\n\n$0.62\n\n$0.65\n\nQ2\n\nQ1\n\n$0.13 $0.13 $0.13\n\n$0.26 $0.26 $0.26\n\n$0.32\n\n$0.62 $0.56\n\n$0.28\n\nFY15\n\nFY16\n\nFY17\n\nFY18\n\nFY19\n\nFY20\n\nFY21\n\nFY22\n\nFY23\n\n(1) Please see table on page 110 for",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SWKS",
"name": "Skyworks Solutions, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 14.44076,
"sentiment_score": 0.7269,
"highlights": [
{
"highlight": "March 28, 2024\n\nDear Stockholder:\n\nI am pleased to invite you to attend the 2024 Annual Meeting of Stockholders (the \"Annual Meeting\") of <em>Skyworks</em> <em>Solutions</em>, <em>Inc</em>., to be held at:\n\nTime: 11:00 a.m.",
"sentiment": 0.7269,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SWKS.MX",
"name": "Skyworks Solutions, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Technology",
"match_score": 14.440504,
"sentiment_score": 0.7269,
"highlights": [
{
"highlight": "March 28, 2024\n\nDear Stockholder:\n\nI am pleased to invite you to attend the 2024 Annual Meeting of Stockholders (the \"Annual Meeting\") of <em>Skyworks</em> <em>Solutions</em>, <em>Inc</em>., to be held at:\n\nTime: 11:00 a.m.",
"sentiment": 0.7269,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0L77.L",
"name": "Skyworks Solutions, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 14.440554,
"sentiment_score": 0.7269,
"highlights": [
{
"highlight": "March 28, 2024\n\nDear Stockholder:\n\nI am pleased to invite you to attend the 2024 Annual Meeting of Stockholders (the \"Annual Meeting\") of <em>Skyworks</em> <em>Solutions</em>, <em>Inc</em>., to be held at:\n\nTime: 11:00 a.m.",
"sentiment": 0.7269,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "ca7d3e0e-a219-43a8-b96c-1cf4a681e7ed",
"title": "S&P 500 Earnings: Market Cap Weight Vs. Earnings Weight Updated",
"description": "A reader asked last week what was driving the S&P 500 earnings growth. Fact is the biggest market cap stocks, some of which have the larger earnings weights, are pushing the market higher",
"keywords": "",
"snippet": "sankai\n\nA reader asked last week what was driving the S&P 500 earnings growth, and while you could write a book about it, the fact is, the biggest market cap st...",
"url": "https://seekingalpha.com/article/4681119-s-and-p-500-earnings-market-cap-weight-vs-earnings-weight-updated",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1498123628/image_1498123628.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-03-29T00:00:00.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "GOOGL",
"name": "Alphabet Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 15.786768,
"sentiment_score": 0.4111,
"highlights": [
{
"highlight": "<em>Alphabet</em> (GOOG) (<em>GOOGL</em>): 3.71% mkt cap wt (combined) vs. a 3.62% earnings weight\n\n7.) Berkshire Class B (BRK.B): 1.72% mkt cap wt vs. a 1.77% earnings weight\n\n8) Eli Lilly (LLY): 1.41% mkt cap wt vs. “unknown” earnings weight\n\n9.) Broadcom (AVGO): 1.31% mkt cap wt vs. “unknown” earnings weight\n\n10.)",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "JPMorgan (JPM): 1.31% market cap wt vs. a 2.66% earnings weight\n\nSource: Morningstar for market cap weights, LSEG for earnings weights\n\nTotal Top 10 market cap weight: 33.49%\n\nTotal Top 10 earnings weight: 24.11% (with two unknowns)\n\nJust think about this data: Within 10 names in the S&P 500 (and that’s combining <em>Alphabet</em>, you have 1/3rd of the entire",
"sentiment": 0.3818,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "22ef6aa7-677a-4efa-8cea-a904b9893be4",
"title": "S&P 500 Gains and Losses Today: Index Posts Record Close To End First Quarter",
"description": "The S&P 500 added 0.1% on Thursday, March 28, 2024, posting an all-time closing high on the final trading day in the first quarter of 2024.",
"keywords": "",
"snippet": "Key Takeaways The S&P 500 added 0.1% on Thursday, March 28, 2024, posting an all-time closing high on the final trading day in the first quarter of 2024.\n\nShare...",
"url": "https://www.investopedia.com/s-and-p-500-gains-and-losses-today-index-posts-record-close-to-end-first-quarter-8621892",
"image_url": "https://www.investopedia.com/thmb/Vvp-zRbbQ0-XNhZ6us_ERZCn3VM=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/latestGainersLosers-2962f2dc159246429be6719c2f13f84b.png",
"language": "en",
"published_at": "2024-03-28T20:49:09.000000Z",
"source": "investopedia.com",
"relevance_score": null,
"entities": [
{
"symbol": "^GSPC",
"name": "S&P 500",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "index",
"industry": "N/A",
"match_score": 101.49544,
"sentiment_score": 0.31306,
"highlights": [
{
"highlight": "Key Takeaways The <em>S</em>&<em>P</em> <em>500</em> added 0.1% on Thursday, March 28, 2024, posting an all-time closing high on the final trading day in the first quarter of 2024.\n\nShares of Estee Lauder soared after Bank of America upgraded the stock, forecasting meaningful growth for the beauty products maker.",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>S</em>&<em>P</em> <em>500</em> advanced 0.1%, ending the quarter at an all-time closing high. Including the uptick on Thursday, the <em>S</em>&<em>P</em> <em>500</em> was up around 10% for the first three months of the year, marking its strongest first-quarter performance since 2019. The Dow also added 0.1% on the day, while the tech-heavy Nasdaq slipped 0.1%.",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "Shares of cosmetics company Estee Lauder (EL) led the <em>S</em>&<em>P</em> <em>500</em> higher, soaring 6.3% after Bank of America Securities upgraded the stock to \"buy\" and increased its price target to $170 from $160. Analysts anticipate meaningful growth for the beauty products maker, highlighting its cost-saving initiatives and adaptations to slower sales in China.",
"sentiment": 0.9217,
"highlighted_in": "main_text"
},
{
"highlight": "(CCL) shares posted the day's steepest losses among <em>S</em>&<em>P</em> <em>500</em> stocks, dropping 4.9% after the cruise operator said it anticipates up to $10 million in losses related to the collapse of Baltimore's Francis Scott Key Bridge early Tuesday morning.",
"sentiment": -0.7506,
"highlighted_in": "main_text"
},
{
"highlight": "<em>S</em>&<em>P</em> <em>500</em> Gains and Losses Today: Index Posts Record Close To End First Quarter",
"sentiment": -0.0772,
"highlighted_in": "title"
}
]
},
{
"symbol": "WBA",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 23.933495,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "<em>Walgreens</em> <em>Boots</em> <em>Alliance</em> (WBA) shares jumped 3.2% as the pharmacy giant posted better-than-expected sales results for its fiscal second quarter.",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ON",
"name": "ON Semiconductor Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 14.074944,
"sentiment_score": -0.0772,
"highlights": [
{
"highlight": "Shares of intelligent power and sensing chipmaker <em>ON</em> <em>Semiconductor</em> (ON) fell 2.7%. Semiconductor stocks came under pressure as analysts at UBS highlighted several warning signals for the industry, including a vulnerable outlook for global pricing momentum.",
"sentiment": -0.0772,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.431934,
"sentiment_score": 0.836,
"highlights": [
{
"highlight": "<em>Moderna</em> (MRNA) shares fell 3.6% on Thursday, reversing gains posted in the prior session amid reports the vaccine maker had secured $750 million from Blackstone Life Sciences for its flu program.\n\nShares of intelligent power and sensing chipmaker ON Semiconductor (ON) fell 2.7%.",
"sentiment": 0.836,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "3fa719f2-564f-492d-aedc-42d742a228d4",
"title": "Stock market surge rewards S&P 500 with best start since 2019",
"description": "A robust quarter for the tech and financial sectors boosted the S&P to its best quarter since 2019.",
"keywords": "",
"snippet": "Stocks wrapped up a monster first quarter on a subdued note Thursday, with both the S&P 500 and Nasdaq posting double-digit gains the first three months of 2024...",
"url": "https://www.washingtonpost.com/business/2024/03/28/stock-market-first-quarter-2024/",
"image_url": "https://www.washingtonpost.com/wp-apps/imrs.php?src=https://arc-anglerfish-washpost-prod-washpost.s3.amazonaws.com/public/OFT3BBHZTII6RBSCZFYYUJLMXU.jpg&w=1440",
"language": "en",
"published_at": "2024-03-28T20:28:01.000000Z",
"source": "washingtonpost.com",
"relevance_score": null,
"entities": [
{
"symbol": "^GSPC",
"name": "S&P 500",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "index",
"industry": "N/A",
"match_score": 111.63283,
"sentiment_score": 0.797825,
"highlights": [
{
"highlight": "Stocks wrapped up a monster first quarter on a subdued note Thursday, with both the <em>S</em>&<em>P</em> <em>500</em> and Nasdaq posting double-digit gains the first three months of 2024 — powered by investors’ optimism about the state of the economy.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>S</em>&<em>P</em> <em>500</em> gained 10.8 percent in the first quarter, continuing a rally that began in late 2023 and notching its strongest start to the year since 2019. The tech-heavy Nasdaq gained 10.9 percent.",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>S</em>&<em>P</em> <em>500</em> closed at 5,254, up 0.1 percent for the day, while the tech-heavy Nasdaq fell 0.1 percent to close at 16,379.\n\nThe strong quarter for all three indexes extends gains in the final months of 2023, when a cadre of tech stocks, dubbed the Magnificent 7, pulled the market higher.",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Stock market surge rewards <em>S</em>&<em>P</em> <em>500</em> with best start since 2019",
"sentiment": 0.8074,
"highlighted_in": "title"
}
]
},
{
"symbol": "AAPL",
"name": "Apple Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 11.46245,
"sentiment_score": 0,
"highlights": [
{
"highlight": "The Dow, which includes 30 large companies traded on U.S. stock exchanges ― so-called blue-chip companies, including <em>Apple</em>, Boeing, Nike and Walmart — is a closely watched bellwether of how the stock market is doing.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVDA",
"name": "NVIDIA Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 13.033785,
"sentiment_score": 0.7717,
"highlights": [
{
"highlight": "Companies that benefited from the hype around advancements in artificial intelligence wowed Wall Street the most, specifically Microsoft and <em>Nvidia</em>.\n\nBut the market’s performance so far in 2024 has also broadened the rally.",
"sentiment": 0.7717,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MSFT",
"name": "Microsoft Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 11.798445,
"sentiment_score": 0.7717,
"highlights": [
{
"highlight": "Companies that benefited from the hype around advancements in artificial intelligence wowed Wall Street the most, specifically <em>Microsoft</em> and Nvidia.\n\nBut the market’s performance so far in 2024 has also broadened the rally.",
"sentiment": 0.7717,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "^DJI",
"name": "Dow Jones Industrial Average",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "index",
"industry": "N/A",
"match_score": 34.329536,
"sentiment_score": 0.91,
"highlights": [
{
"highlight": "The <em>Dow</em> <em>Jones</em> <em>Industrial</em> <em>Average</em> also notched a respectable first quarter with a gain of 5.4 percent, which analysts took as a welcome sign that the current rally isn’t wholly dependent on Big Tech.\n\nThe market surge is driven by the continued strength of the economy, with consumers continuing to open up their wallets, analysts said.",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "1664f50f-09d1-4216-92bb-55170082d465",
"title": "Accelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call Transcript",
"description": "Accelerate Diagnostics Inc. (NASDAQ:NASDAQ:AXDX) Q4 2023 Results Conference Call March 28, 2024 4:30 PM ETCompany ParticipantsLaura Pierson - Investor...",
"keywords": "",
"snippet": "Accelerate Diagnostics Inc. (NASDAQ:AXDX) Q4 2023 Results Conference Call March 28, 2024 4:30 PM ET\n\nCompany Participants\n\nLaura Pierson - Investor Relations Of...",
"url": "https://seekingalpha.com/article/4681118-accelerate-diagnostics-inc-axdx-q4-2023-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-28T23:50:04.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "AXDX",
"name": "Accelerate Diagnostics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 147.09811,
"sentiment_score": 0.36245,
"highlights": [
{
"highlight": "<em>Accelerate</em> <em>Diagnostics</em> <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ:AXDX</em>) Q4 2023 Results Conference Call March 28, 2024 4:30 PM ET\n\nCompany Participants\n\nLaura Pierson - Investor Relations Officer\n\nJack Phillips - CEO, President and Director\n\nDavid Patience - CFO, Principal Financial Officer and Principal Accounting Officer\n\nConference Call Participants\n\nDustin Scaringe - William Blair\n\nOperator\n\nHello, and",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "welcome to the <em>Accelerate</em> <em>Diagnostics</em> Fourth Quarter and Full Year 2023 Earnings Call.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "I would now like to hand the call to Laura Pierson with <em>Accelerate</em> <em>Diagnostics</em>. Laura, please go ahead.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "Appreciate your continued interest in <em>Accelerate</em> <em>Diagnostics</em> and the work that we're doing around sepsis and AMR, such an important area in the space of health care and becoming more and more important. I just want to wrap up on a few important items that we talked about today.",
"sentiment": 0.9253,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Accelerate</em> <em>Diagnostics</em> <em>Inc</em>. (AXDX) Q4 2023 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "e2814837-6c54-45c7-9e84-8ec63b4d313d",
"title": "Nuvve Holding Corp. (NVVE) Q4 2023 Earnings Call Transcript",
"description": "Nuvve Holding Corp. (NASDAQ:NASDAQ:NVVE) Q4 2023 Results Conference Call March 28, 2024 5:00 PM ETCompany ParticipantsCaroline King - Director, Joele...",
"keywords": "",
"snippet": "Nuvve Holding Corp. (NASDAQ:NVVE) Q4 2023 Results Conference Call March 28, 2024 5:00 PM ET\n\nCompany Participants\n\nCaroline King - Director, Joele Frank\n\nGregor...",
"url": "https://seekingalpha.com/article/4681117-nuvve-holding-corp-nvve-q4-2023-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-28T23:48:07.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "NVVEW",
"name": "Nuvve Holding Corp.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 162.02594,
"sentiment_score": 0.35015,
"highlights": [
{
"highlight": "<em>Nuvve</em> <em>Holding</em> <em>Corp</em>. (NASDAQ:NVVE) Q4 2023 Results Conference Call March 28, 2024 5:00 PM ET\n\nCompany Participants\n\nCaroline King - Director, Joele Frank\n\nGregory Poilasne - Chief Executive Officer\n\nDavid Robson - Chief Financial Officer\n\nOperator\n\nGreetings, and welcome to <em>Nuvve</em> <em>Holding</em> <em>Corp</em>. Fourth Quarter Earnings Conference Call.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Nuvve</em> <em>Holding</em> <em>Corp</em>. (NVVE) Q4 2023 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "NVVE",
"name": "Nuvve Holding Corp.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 216.77971,
"sentiment_score": 0.35015,
"highlights": [
{
"highlight": "<em>Nuvve</em> <em>Holding</em> <em>Corp</em>. (<em>NASDAQ:NVVE</em>) Q4 2023 Results Conference Call March 28, 2024 5:00 PM ET\n\nCompany Participants\n\nCaroline King - Director, Joele Frank\n\nGregory Poilasne - Chief Executive Officer\n\nDavid Robson - Chief Financial Officer\n\nOperator\n\nGreetings, and welcome to <em>Nuvve</em> <em>Holding</em> <em>Corp</em>. Fourth Quarter Earnings Conference Call.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Nuvve</em> <em>Holding</em> <em>Corp</em>. (<em>NVVE</em>) Q4 2023 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "cb88e38a-67d5-4fa3-a59e-6e7f4d20b818",
"title": "Semtech (NASDAQ:SMTC) Surprises With Q4 Sales, Stock Jumps 10.1% By Stock Story",
"description": "Semtech (NASDAQ:SMTC) Surprises With Q4 Sales, Stock Jumps 10.1%",
"keywords": "",
"snippet": "Semiconductor company Semtech (NASDAQ: (NASDAQ: )) reported Q4 CY2023 results beating Wall Street analysts' expectations, with revenue up 15.2% year on year to ...",
"url": "https://www.investing.com/news/stock-market-news/semtech-nasdaqsmtc-surprises-with-q4-sales-stock-jumps-101-3357680",
"image_url": "https://i-invdn-com.investing.com/news/LYNXNPEC180BO_L.jpg",
"language": "en",
"published_at": "2024-03-28T21:00:46.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "SMTX",
"name": "SMTC Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 15.397073,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Semtech (<em>SMTC</em>) Q4 CY2023 Highlights:\n\nRevenue: $192.9 million vs analyst estimates of $190.7 million (1.2% beat)\n\n$192.9 million vs analyst estimates of $190.7 million (1.2% beat) EPS (non-GAAP): -$0.06 vs analyst expectations of -$0.04 (34.7% miss)\n\n-$0.06 vs analyst expectations of -$0.04 (34.7% miss) Revenue Guidance for Q1 CY2024 is $200 million",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SMTC",
"name": "Semtech Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 80.187744,
"sentiment_score": 0.292643,
"highlights": [
{
"highlight": "Semiconductor company <em>Semtech</em> (NASDAQ: (NASDAQ: )) reported Q4 CY2023 results beating Wall Street analysts' expectations, with revenue up 15.2% year on year to $192.9 million. Guidance for next quarter's revenue was also optimistic at $200 million at the midpoint, 2.4% above analysts' estimates.",
"sentiment": -0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Is now the time to buy <em>Semtech</em>? Find out by reading the original article on StockStory.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Semtech</em> (SMTC) Q4 CY2023 Highlights:\n\nRevenue: $192.9 million vs analyst estimates of $190.7 million (1.2% beat)\n\n$192.9 million vs analyst estimates of $190.7 million (1.2% beat) EPS (non-GAAP): -$0.06 vs analyst expectations of -$0.04 (34.7% miss)\n\n-$0.06 vs analyst expectations of -$0.04 (34.7% miss) Revenue Guidance for Q1 CY2024 is $200 million",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Operating for more than 60 years, <em>Semtech</em> (<em>NASDAQ:SMTC</em>) is a provider of analog and mixed-signal semiconductors used for Internet of Things systems and cloud connectivity.\n\nSemiconductor ManufacturingThe semiconductor industry is driven by demand for advanced electronic products like smartphones, PCs, servers, and data storage.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Semtech</em> had a decent quarter as its revenue grew 15.2% year on year, topping analysts' estimates by 1.2%. This marks 4 straight quarters of growth, implying that <em>Semtech</em> is in the middle of its cycle, as a typical upcycle generally lasts 8-10 quarters.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Overall, this was an encouraging quarter for <em>Semtech</em>. The stock is up 10.1% after reporting and currently trades at $30.29 per share.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Semtech</em> (<em>NASDAQ:SMTC</em>) Surprises With Q4 Sales, Stock Jumps 10.1% By Stock Story",
"sentiment": 0.2263,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "faa03a96-117a-4aeb-96fb-a0fb17c94544",
"title": "Everspin Technologies VP sells shares to cover tax obligations By Investing.com",
"description": "Everspin Technologies VP sells shares to cover tax obligations",
"keywords": "",
"snippet": "Everspin Technologies Inc . (NASDAQ: ) Vice President of Sales and Business Development, David Schrenk, has recently sold shares of the company's common stock, ...",
"url": "https://www.investing.com/news/company-news/everspin-technologies-vp-sells-shares-to-cover-tax-obligations-93CH-3357857",
"image_url": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
"language": "en",
"published_at": "2024-03-28T23:44:01.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRAM",
"name": "Everspin Technologies, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 110.74823,
"sentiment_score": 0.24395,
"highlights": [
{
"highlight": "<em>Everspin</em> <em>Technologies</em> <em>Inc</em> . (NASDAQ: ) Vice President of Sales and Business Development, David Schrenk, has recently sold shares of the company's common stock, according to the latest SEC filings. The transaction, which took place on March 26, involved the sale of 222 shares at a price of $8.02 each, amounting to a total of $1,780.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Everspin</em> <em>Technologies</em> specializes in manufacturing semiconductor devices and is recognized in the industry for its innovations in magnetoresistive random-access memory (MRAM) technology. The company's stock is publicly traded, and investors can follow its performance on the NASDAQ exchange under the ticker symbol MRAM.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "InvestingPro Insights\n\n<em>Everspin</em> <em>Technologies</em> <em>Inc</em>. (<em>NASDAQ:MRAM</em>) has been navigating the market with a solid financial footing according to the latest data from InvestingPro. With a market capitalization of $169.8 million, the company is showing signs of stability in its valuation.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Everspin</em> <em>Technologies</em> VP sells shares to cover tax obligations By Investing.com",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "dc8f09bd-6035-45c7-8dde-dabfe6a16a7a",
"title": "Everspin Technologies CEO sells shares worth over $4,000 By Investing.com",
"description": "Everspin Technologies CEO sells shares worth over $4,000",
"keywords": "",
"snippet": "Sanjeev Aggarwal, the President and CEO of Everspin Technologies Inc . (NASDAQ: ), has recently sold a portion of his stock in the company. The transaction, whi...",
"url": "https://www.investing.com/news/company-news/everspin-technologies-ceo-sells-shares-worth-over-4000-93CH-3357855",
"image_url": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
"language": "en",
"published_at": "2024-03-28T23:42:06.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "0IJ3.L",
"name": "Everspin Technologies, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 94.214714,
"sentiment_score": 0.490578,
"highlights": [
{
"highlight": "Sanjeev Aggarwal, the President and CEO of <em>Everspin</em> <em>Technologies</em> <em>Inc</em> . (NASDAQ: ), has recently sold a portion of his stock in the company. The transaction, which took place on March 26, 2024, involved the sale of 519 shares at a price of $8.02 each, totaling over $4,000.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Following this transaction, Aggarwal still holds a significant stake in <em>Everspin</em> <em>Technologies</em>, with 494,131 shares remaining in his possession.\n\nInvestors often keep a close eye on insider transactions as they can provide insights into the leadership's perspective on the company's current valuation and future prospects.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Everspin</em> <em>Technologies</em>, headquartered in Chandler, Arizona, specializes in the manufacturing of semiconductor and related devices. The company's commitment to innovation in the memory sector positions it as a notable player in the semiconductor industry.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Shareholders and potential investors can access these filings to stay informed about the financial dealings of <em>Everspin</em> <em>Technologies</em>' executives.\n\nInvestingPro Insights\n\nIn light of the recent insider transaction at <em>Everspin</em> <em>Technologies</em> <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Everspin</em> <em>Technologies</em>, known for its semiconductor innovation, shows a promising financial structure with a market capitalization of approximately $169.8 million.\n\nOne of the InvestingPro Tips highlights that <em>Everspin</em> <em>Technologies</em> is trading at a low P/E ratio relative to its near-term earnings growth, currently standing at 18.21.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "From a performance standpoint, <em>Everspin</em> <em>Technologies</em> has experienced a revenue growth of 6.3% over the last twelve months as of Q4 2023, with a gross profit margin of 58.41%, indicating a strong ability to translate sales into profit.",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "For investors seeking further insights, there are additional InvestingPro Tips available, which can provide a deeper analysis of <em>Everspin</em> <em>Technologies</em>' financial outlook. Using the coupon code PRONEWS24, readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "With 6 more tips listed on InvestingPro for <em>Everspin</em> <em>Technologies</em>, investors can gain a comprehensive understanding of the company's financial nuances and make more informed decisions.\n\nThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Everspin</em> <em>Technologies</em> CEO sells shares worth over $4,000 By Investing.com",
"sentiment": 0.4767,
"highlighted_in": "title"
}
]
},
{
"symbol": "MRAM",
"name": "Everspin Technologies, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 111.48552,
"sentiment_score": 0.48402,
"highlights": [
{
"highlight": "Sanjeev Aggarwal, the President and CEO of <em>Everspin</em> <em>Technologies</em> <em>Inc</em> . (NASDAQ: ), has recently sold a portion of his stock in the company. The transaction, which took place on March 26, 2024, involved the sale of 519 shares at a price of $8.02 each, totaling over $4,000.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Following this transaction, Aggarwal still holds a significant stake in <em>Everspin</em> <em>Technologies</em>, with 494,131 shares remaining in his possession.\n\nInvestors often keep a close eye on insider transactions as they can provide insights into the leadership's perspective on the company's current valuation and future prospects.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Everspin</em> <em>Technologies</em>, headquartered in Chandler, Arizona, specializes in the manufacturing of semiconductor and related devices. The company's commitment to innovation in the memory sector positions it as a notable player in the semiconductor industry.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Shareholders and potential investors can access these filings to stay informed about the financial dealings of <em>Everspin</em> <em>Technologies</em>' executives.\n\nInvestingPro Insights\n\nIn light of the recent insider transaction at <em>Everspin</em> <em>Technologies</em> <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ:MRAM</em>), prospective and current investors might find additional context in the company's financial health and market performance. <em>Everspin</em> <em>Technologies</em>, known for its semiconductor innovation, shows a promising financial structure with a market capitalization of approximately $169.8 million.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "One of the InvestingPro Tips highlights that <em>Everspin</em> <em>Technologies</em> is trading at a low P/E ratio relative to its near-term earnings growth, currently standing at 18.21. This suggests that the stock could be undervalued considering its growth potential.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "From a performance standpoint, <em>Everspin</em> <em>Technologies</em> has experienced a revenue growth of 6.3% over the last twelve months as of Q4 2023, with a gross profit margin of 58.41%, indicating a strong ability to translate sales into profit.",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "For investors seeking further insights, there are additional InvestingPro Tips available, which can provide a deeper analysis of <em>Everspin</em> <em>Technologies</em>' financial outlook. Using the coupon code PRONEWS24, readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "With 6 more tips listed on InvestingPro for <em>Everspin</em> <em>Technologies</em>, investors can gain a comprehensive understanding of the company's financial nuances and make more informed decisions.\n\nThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Everspin</em> <em>Technologies</em> CEO sells shares worth over $4,000 By Investing.com",
"sentiment": 0.4767,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "61e98266-e792-4329-baeb-a5894fbdc9e4",
"title": "Kellogg W K Foundation Trust sells $4.46 million in Kellanova shares By Investing.com",
"description": "Kellogg W K Foundation Trust sells $4.46 million in Kellanova shares",
"keywords": "",
"snippet": "The Kellogg (NYSE: ) W K Foundation Trust, a major shareholder in Kellanova, has sold a significant portion of its holdings in the company. On March 28, 2024, t...",
"url": "https://www.investing.com/news/company-news/kellogg-w-k-foundation-trust-sells-446-million-in-kellanova-shares-93CH-3357823",
"image_url": "https://i-invdn-com.investing.com/news/",
"language": "en",
"published_at": "2024-03-28T22:36:08.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "NTRS",
"name": "Northern Trust Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 17.100887,
"sentiment_score": 0.64275,
"highlights": [
{
"highlight": "Tsoumas, and The <em>Northern</em> <em>Trust</em> (NASDAQ: ) Company as Trustees, remains a significant shareholder with the W.K. Kellogg Foundation as the sole beneficiary.\n\nThe sale was part of a planned divestiture process, as disclosed in the remarks of the SEC filing, and was facilitated by Craig R.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Carberry, Associate General Counsel of The <em>Northern</em> <em>Trust</em> Company, acting as Corporate Trustee of the W.K. Kellogg Foundation Trust.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NTRSO",
"name": "Northern Trust Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 17.100895,
"sentiment_score": 0.64275,
"highlights": [
{
"highlight": "Tsoumas, and The <em>Northern</em> <em>Trust</em> (NASDAQ: ) Company as Trustees, remains a significant shareholder with the W.K. Kellogg Foundation as the sole beneficiary.\n\nThe sale was part of a planned divestiture process, as disclosed in the remarks of the SEC filing, and was facilitated by Craig R.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Carberry, Associate General Counsel of The <em>Northern</em> <em>Trust</em> Company, acting as Corporate Trustee of the W.K. Kellogg Foundation Trust.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "K",
"name": "Kellogg Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 47.97664,
"sentiment_score": 0.687983,
"highlights": [
{
"highlight": "The <em>Kellogg</em> (NYSE: ) W K Foundation Trust, a major shareholder in Kellanova, has sold a significant portion of its holdings in the company. On March 28, 2024, the Trust sold 77,800 shares of Kellanova common stock at a price of $57.3397 per share, totaling approximately $4.46 million.",
"sentiment": 0.8957,
"highlighted_in": "main_text"
},
{
"highlight": "Kellanova, known by its stock ticker <em>NYSE:K</em>, is a company in the grain mill products industry with a rich history dating back to its former name, <em>Kellogg</em> Co.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Kellogg</em> Foundation as the sole beneficiary.\n\nThe sale was part of a planned divestiture process, as disclosed in the remarks of the SEC filing, and was facilitated by Craig R. Carberry, Associate General Counsel of The Northern Trust Company, acting as Corporate Trustee of the W.K. <em>Kellogg</em> Foundation Trust.",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Investors and market watchers often pay close attention to the buying and selling activities of major shareholders such as the <em>Kellogg</em> W K Foundation Trust, as these transactions can provide insights into the stock's performance and the company's valuation.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "InvestingPro Insights\n\nAs investors digest the recent sale of Kellanova shares by the <em>Kellogg</em> W K Foundation Trust, real-time data from InvestingPro paints a detailed financial picture of the company.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Kellogg</em> W K Foundation Trust sells $4.46 million in Kellanova shares By Investing.com",
"sentiment": 0.6705,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "8c069873-b3b3-4035-8124-6b0a6ff87bef",
"title": "AstroNova VP Stephen Petrarca sells $88,950 in company stock By Investing.com",
"description": "AstroNova VP Stephen Petrarca sells $88,950 in company stock",
"keywords": "",
"snippet": "AstroNova, Inc. (NASDAQ:ALOT) Vice President Stephen M. Petrarca recently sold shares of the company's common stock, according to the latest Form 4 filing with ...",
"url": "https://www.investing.com/news/company-news/astronova-vp-stephen-petrarca-sells-88950-in-company-stock-93CH-3357692",
"image_url": "https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg",
"language": "en",
"published_at": "2024-03-28T21:06:12.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "ALOT",
"name": "AstroNova, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 70.53723,
"sentiment_score": 0.546925,
"highlights": [
{
"highlight": "<em>AstroNova</em>, <em>Inc</em>. (<em>NASDAQ:ALOT</em>) Vice President Stephen M. Petrarca recently sold shares of the company's common stock, according to the latest Form 4 filing with the Securities and Exchange Commission. On March 27, Petrarca sold 5,000 shares at a weighted average price of $17.79, for a total transaction value of $88,950.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "Following the sale, Petrarca still owns 27,784 shares of <em>AstroNova</em> stock, indicating a continued investment in the company's future.\n\n<em>AstroNova</em>, based in West Warwick, Rhode Island, specializes in computer peripheral equipment and has a rich history of name changes and industry shifts.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "Investors and shareholders of <em>AstroNova</em> can request detailed information about the exact number of shares sold at each price point within the specified range by reaching out to the company or the SEC.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "This sale demonstrates a significant transaction by a key executive within <em>AstroNova</em> and is often watched closely by market participants for potential insights into executive sentiment about the company's prospects.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "With a market capitalization of $132.45 million, <em>AstroNova</em> is trading at a P/E ratio of 28.14, which adjusts to a more attractive 21.15 when considering the last twelve months as of Q4 2024.",
"sentiment": 0.4877,
"highlighted_in": "main_text"
},
{
"highlight": "Moreover, <em>AstroNova</em> has shown a robust free cash flow yield, as implied by its valuation. This is a vital sign of financial health and efficiency, hinting that the company can sustain and potentially grow its operations through the cash it generates.",
"sentiment": 0.8555,
"highlighted_in": "main_text"
},
{
"highlight": "For those interested in deeper analysis and more InvestingPro Tips, <em>AstroNova</em> has an additional 15 tips available on InvestingPro. To take advantage of these insights, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstroNova</em> VP Stephen Petrarca sells $88,950 in company stock By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "ffa52a57-f89d-411b-9490-fe2b0ba0c76f",
"title": "Vir Biotechnology CFO sells shares worth over $59,000 By Investing.com",
"description": "Vir Biotechnology CFO sells shares worth over $59,000",
"keywords": "",
"snippet": "Vir Biotechnology (NASDAQ: ) Inc.’s (NASDAQ:VIR) Executive Vice President and Chief Financial Officer, Lee Sung, recently sold 6,008 shares of the company's c...",
"url": "https://www.investing.com/news/company-news/vir-biotechnology-cfo-sells-shares-worth-over-59000-93CH-3357256",
"image_url": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
"language": "en",
"published_at": "2024-03-28T16:22:13.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "VIR",
"name": "Vir Biotechnology, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 83.937965,
"sentiment_score": 0.32192,
"highlights": [
{
"highlight": "<em>Vir</em> <em>Biotechnology</em> (NASDAQ: ) Inc.’s (<em>NASDAQ:VIR</em>) Executive Vice President and Chief Financial Officer, Lee Sung, recently sold 6,008 shares of the company's common stock. The transaction, which took place on March 27, 2024, was executed at a price of $9.8875 per share, resulting in a total sale amount exceeding $59,000.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Following this transaction, Lee Sung’s direct holdings in <em>Vir</em> <em>Biotechnology</em> stand at 100,492 shares.\n\n<em>Vir</em> <em>Biotechnology</em>, a company specializing in biological products, did not disclose any specific reason for the stock sale beyond the automatic nature tied to tax obligations.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "According to InvestingPro data, <em>Vir</em> <em>Biotechnology</em> holds a market capitalization of approximately $1.38 billion.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For those looking for more comprehensive analysis, InvestingPro offers additional insights on <em>Vir</em> <em>Biotechnology</em>, including a total of 9 InvestingPro Tips that could further inform investment decisions.",
"sentiment": 0.3102,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Vir</em> <em>Biotechnology</em> CFO sells shares worth over $59,000 By Investing.com",
"sentiment": 0.4767,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "ab64a923-d9c6-4f88-a4b4-9851ced08ef2",
"title": "CVD Equipment Corporation (CVV) Q4 2023 Earnings Call Transcript",
"description": "CVD Equipment Corporation (NASDAQ:NASDAQ:CVV) Q4 2023 Earnings Conference Call March 28, 2024 5:00 PM ETCompany ParticipantsEmmanuel Lakios - President...",
"keywords": "",
"snippet": "CVD Equipment Corporation (NASDAQ:CVV) Q4 2023 Earnings Conference Call March 28, 2024 5:00 PM ET\n\nCompany Participants\n\nEmmanuel Lakios - President & CEO\n\nRich...",
"url": "https://seekingalpha.com/article/4681113-cvd-equipment-corporation-cvv-q4-2023-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-28T23:27:09.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "CVV",
"name": "CVD Equipment Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 171.1388,
"sentiment_score": 0.072367,
"highlights": [
{
"highlight": "<em>CVD</em> <em>Equipment</em> <em>Corporation</em> (<em>NASDAQ:CVV</em>) Q4 2023 Earnings Conference Call March 28, 2024 5:00 PM ET\n\nCompany Participants\n\nEmmanuel Lakios - President & CEO\n\nRich Catalano - VP, CFO\n\nConference Call Participants\n\nBrett Reiss - Janney Montgomery Scott\n\nOperator\n\nGreetings, and thank you for standing by, and welcome to the <em>CVD</em> <em>equipment</em> Corporation's Fourth",
"sentiment": 0.8979,
"highlighted_in": "main_text"
},
{
"highlight": "The decrease was primarily attributable to lower revenue in our <em>CVD</em> <em>equipment</em> segment of approximately $0.4 million related to lower PVT 150 system revenues that was offset by higher aerospace revenue.\n\nOur CVD materials business was lower by $2 million.",
"sentiment": -0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVD</em> <em>Equipment</em> <em>Corporation</em> (CVV) Q4 2023 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "c7c274c0-6663-4a91-bf87-0d67d16c7670",
"title": "Iridex's Strategic Review Process Should Bear Fruit 'Soon'",
"description": "Iridex's strategic review process is set to unlock shareholder value as it considers selling its retina business. Click here to read my analysis of IRIX stock.",
"keywords": "",
"snippet": "Zorica Nastasic\n\nIridex Corporation (NASDAQ:IRIX), a global leader in ophthalmic medical technology for the treatment of retinal and glaucoma diseases, announce...",
"url": "https://seekingalpha.com/article/4681110-iridexs-strategic-review-process-should-bear-fruit-soon",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1425487363/image_1425487363.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2024-03-28T23:12:12.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "IRIX",
"name": "IRIDEX Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.522682,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Zorica Nastasic\n\n<em>Iridex</em> <em>Corporation</em> (<em>NASDAQ:IRIX</em>), a global leader in ophthalmic medical technology for the treatment of retinal and glaucoma diseases, announced last year that they had begun a \"strategic review\" to \"unlock shareholder value.\"",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "NASDAQ",
"total_documents": 1627,
"sentiment_avg": 0.2819337461197923
}
]
}
Other details
Country
- us
- 5,275